Get the Stockscreener App
14.06
3.08%
0.42
Pre-market:
14.02
-0.04
-0.28%
Cullinan Therapeutics Inc stock is traded at $14.06, with a volume of 1.16M.
It is up +3.08% in the last 24 hours and down -2.09% over the past month.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
See More
Previous Close:
$13.64
Open:
$13.87
24h Volume:
1.16M
Relative Volume:
1.40
Market Cap:
$851.00M
Revenue:
-
Net Income/Loss:
$-219.88M
P/E Ratio:
-3.7757
EPS:
-3.7238
Net Cash Flow:
$-175.76M
1W Performance:
+7.08%
1M Performance:
-2.09%
6M Performance:
+134.72%
1Y Performance:
+69.40%
1-Day Range:
$13.79
$14.74
1-Week Range:
$12.40
$14.74
52-Week Range:
$5.68
$16.74
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Name
Cullinan Therapeutics Inc
Sector
Industry
Phone
617-410-4650
Address
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
14.06 | 825.58M | 0 | -219.88M | -175.76M | -3.7238 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-26 | Initiated | Citigroup | Buy |
| Feb-02-26 | Initiated | Guggenheim | Buy |
| Aug-21-25 | Resumed | H.C. Wainwright | Buy |
| Jun-11-25 | Resumed | Stifel | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| May-01-24 | Initiated | Stifel | Buy |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jun-15-23 | Initiated | TD Cowen | Outperform |
| Nov-21-22 | Initiated | BTIG Research | Buy |
| Apr-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-02-21 | Initiated | Evercore ISI | Outperform |
| Feb-02-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-02-21 | Initiated | SVB Leerink | Outperform |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
View All
Cullinan Therapeutics Inc Stock (CGEM) Latest News
Clear Street reiterates Cullinan Oncology stock rating on Gilead deal validation - Investing.com
Potential of Cullinan Therapeutics (CGEM) Highlighted by Recent Acquisition - GuruFocus
Swing Trade: Does Cullinan Therapeutics Inc have strong EBITDA marginsMarket Risk Analysis & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Cullinan Therapeutics to lead new discussions on next-generation immune therapies - Traders Union
Decliners Report: What is Cullinan Therapeutics Incs valuation compared to sector2026 PostEarnings & Target Return Focused Picks - baoquankhu1.vn
Rate Cut: Whats the RSI of Cullinan Therapeutics Inc stockMarket Activity Summary & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
CGEM Earnings History & Surprises | EPS & Revenue Results | CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) - ChartMill
Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data - MarketBeat
Whale Trades: Can Cullinan Therapeutics Inc outperform under higher oil pricesDividend Hike & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Guggenheim Reaffirms Their Buy Rating on Cullinan Management (CGEM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Cullinan Management (CGEM) and Pfizer (PFE) - The Globe and Mail
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Cullinan Therapeutics (CGEM): Wedbush Raises Price Target to $36 - GuruFocus
Stifel raises Cullinan Oncology stock price target on autoimmune progress By Investing.com - Investing.com Australia
CGEM: Key T-cell engager programs advance toward pivotal milestones and data readouts in 2026 - TradingView
Cullinan Therapeutics: Q4 Earnings InsightsCullinan Therapeutics (NASDAQ:CGEM) - Benzinga
CGEM: 2026 will be pivotal with key data and regulatory milestones for lead T-cell engager programs - TradingView
Cullinan Oncology (CGEM) Projects Strong Cash Position into 2029 - GuruFocus
Cullinan Therapeutics Reports 2025 Financial Results, Updates on CLN-978, Zipalertinib NDA, and 2026 Clinical Milestones - Minichart
Cullinan Therapeutics Inc (CGEM) Reports Q4 Earnings - AlphaStreet
Stifel raises Cullinan Oncology stock price target on autoimmune progress - Investing.com
Cullinan Therapeutics (CGEM) Reports Q4 Loss of $0.77 Per Share, Flat Year-Over-Year - AlphaStreet
Cullinan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Cullinan Therapeutics 2025 10-K: Advancing First-in-Class Therapies for Autoimmune Diseases and Cancer, Risks, and Strategic Developments - Minichart
Cullinan Therapeutics 2025 Financial Report: Q4 Loss Beats EstimatesNews and Statistics - IndexBox
Cullinan Therapeutics (CGEM) Anticipates Major Developments thro - GuruFocus
Cullinan Therapeutics: Fourth Quarter Earnings Overview - Bitget
Earnings Flash (CGEM) Cullinan Therapeutics Posts Q4 Net Loss $0.77 a Share, vs. FactSet Est of $0.77 Loss - marketscreener.com
Cullinan Therapeutics (NASDAQ:CGEM) Releases Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Cullinan Therapeutics 10-K — $0 Revenue, Net Loss $219.9M - TradingView
CGEM: Robust cash reserves and advancing clinical pipeline position for multiple 2026 catalysts - TradingView
Cullinan Therapeutics (Nasdaq: CGEM) details 2025 loss and cash runway into 2029 - Stock Titan
Cullinan Therapeutics: Q4 Earnings Snapshot - whas11.com
Cullinan Therapeutics Q4 net loss widens - TradingView
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 ... - Bluefield Daily Telegraph
BRIEF-Cullinan Therapeutics Q4 Operating Expenses USD 55.259 Million - TradingView
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire
Jennifer Michaelson Sells 8,000 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Cullinan Therapeutics (CGEM) CSO trades options and sells shares - Stock Titan
Cullinan Therapeutics (CGEM) price target increased by 19.75% to 32.84 - MSN
Cullinan Therapeutics Maps 2026 Data Catalysts for Autoimmune CLN-978, AML CLN-049 at TD Cowen Conference - MarketBeat
Blue Owl Capital Holdings LP Has $14.89 Million Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
What is Cullinan Therapeutics Incs valuation compared to sector2025 Biggest Moves & Precise Buy Zone Tips - baoquankhu1.vn
Can Cullinan Therapeutics Inc generate free cash flowWeekly Stock Recap & Smart Money Movement Tracker - baoquankhu1.vn
Jennifer Michaelson (CGEM) files Form 144: option exercise and 10b5-1 sales - Stock Titan
[SCHEDULE 13G] Cullinan Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
CGEM: Transformational milestones and pivotal data for autoimmune and AML programs expected by 2026 - TradingView
CGEM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Cullinan Therapeutics (CGEM) Stock Analysis: Exploring A 101% Upside Potential - DirectorsTalk Interviews
Cullinan Therapeutics (NASDAQ:CGEM) Shares Up 7.6%Here's Why - MarketBeat
Cullinan Therapeutics Inc Stock (CGEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):